Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study

FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion (FUTURE) 3 was a 24-week open-label, prospective, and randomized phase 3 study that assessed the pharmacokinetics of bosentan 2 mg/kg b.i.d. or t.i.d. in children with pulmonary arterial hypertension (PAH). We report findings from a post-hoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Beghetti, Maurice, Berger, Rolf M. F., Bonnet, Damien, Grill, Simon, Lesage, Catherine, Lemarie, Jean-Christophe, Ivy, D. Dunbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242164/
https://www.ncbi.nlm.nih.gov/pubmed/34222150
http://dx.doi.org/10.3389/fped.2021.681538

Ejemplares similares

Ejemplares similares